Concord Biotech
Biotechnology · CONCORDBIO
Mid CapHealthcareHigh Growth
Ankur Vaid
Joint Managing Director & CEO · Pragmatic
Company DNA
Founder-Centric
About
Concord Biotech is a Mid Cap company in the Healthcare sector, listed on NSE as CONCORDBIO. With a market cap of ₹12K Cr and revenue of ₹1K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. High promoter stake and active leadership involvement, fostering a vision-heavy decision-making environment. Its strategic mandate: Needs to scale specialized fermentation-based API manufacturing to capture global market share in high-barrier pharmaceutical segments.
FAQ
What kind of company is Concord Biotech?
Concord Biotech is a Mid Cap Healthcare company (CONCORDBIO) in the High Growth phase with a market cap of ₹12K Cr. It is classified as Founder-Centric in culture.
What is Concord Biotech's culture and work environment like?
Concord Biotech has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. High promoter stake and active leadership involvement, fostering a vision-heavy decision-making environment.
Who leads Concord Biotech?
Concord Biotech is led by Ankur Vaid (Joint Managing Director & CEO), a Pragmatic leader with 23 years of experience.
What are Concord Biotech's financials?
Concord Biotech reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of 18.5%. Operating margin: 39.3%. Market cap: ₹12K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
High promoter stake and active leadership involvement, fostering a vision-heavy decision-making environment.
Mandate
Needs to scale specialized fermentation-based API manufacturing to capture global market share in high-barrier pharmaceutical segments.
Needs to scale specialized fermentation-based API manufacturing to capture global market share in high-barrier pharmaceutical segments.
Financials
Revenue FY25₹1K Cr
PAT FY25₹372 Cr
Rev CAGR 5Y18.5%
OPM39.3%
NPM31.5%
ROE20.5%
ROCE25%
P/E39.8
Fwd P/E28.8
P/B6.8
D/E0.1
Mkt Cap₹12K Cr
Promoter74.7%
Institutional12.6%
Similar Culture
Could You Lead Concord Biotech?
Take the Genome Benchmark →